Thrivent Financial for Lutherans Takes $51.66 Million Position in Icon Plc $ICLR

Thrivent Financial for Lutherans bought a new stake in Icon Plc (NASDAQ:ICLR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 283,502 shares of the medical research company’s stock, valued at approximately $51,660,000. Thrivent Financial for Lutherans owned approximately 0.35% of Icon at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its position in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after purchasing an additional 56 shares during the period. Signaturefd LLC lifted its position in shares of Icon by 12.6% in the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the period. New Wave Wealth Advisors LLC lifted its position in shares of Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the period. Finally, 1900 Wealth Management LLC lifted its position in shares of Icon by 4.4% in the 4th quarter. 1900 Wealth Management LLC now owns 2,430 shares of the medical research company’s stock worth $443,000 after purchasing an additional 103 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Stock Down 0.6%

Icon stock opened at $116.38 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The firm’s fifty day moving average is $109.72 and its 200 day moving average is $144.82. The company has a market capitalization of $9.40 billion, a PE ratio of 15.75, a PEG ratio of 3.04 and a beta of 1.23.

Wall Street Analysts Forecast Growth

ICLR has been the topic of a number of recent analyst reports. Citigroup dropped their price target on shares of Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Weiss Ratings downgraded shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and dropped their price target for the stock from $183.00 to $120.00 in a research report on Wednesday, February 18th. Barclays dropped their price target on shares of Icon from $200.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, March 9th. Finally, Bank of America restated an “underperform” rating and issued a $75.00 price target on shares of Icon in a research report on Thursday, February 12th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Icon has an average rating of “Hold” and a consensus target price of $149.38.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.